| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Biohaven Pharma Hldgs (NYSE:BHVN) reported its Q2 earnings results on Friday, August 5, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Biohaven Pharma Hldgs missed estimated earnings by 48.06%, reporting an EPS of $-3.82 versus an estimate of $-2.58.
Revenue was up $122.15 million from the same period last year.
Last quarter the company beat on EPS by $0.91 which was followed by a 0.56% increase in the share price the next day.
Here's a look at Biohaven Pharma Hldgs's past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -2.53 | -2.04 | -2.40 | -2.74 |
| EPS Actual | -1.62 | -2.32 | -1.91 | -2.62 |
| Revenue Estimate | 181.11M | 173.69M | 128.40M | 78.13M |
| Revenue Actual | 318.85M | 190.01M | 135.74M | 92.93M |
To track all earnings releases for Biohaven Pharma Hldgs visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: BHVN
